Logotype for Tenaya Therapeutics Inc

Tenaya Therapeutics (TNYA) investor relations material

Tenaya Therapeutics H. C. Wainwright Genetic Medicines Virtual Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Tenaya Therapeutics Inc
H. C. Wainwright Genetic Medicines Virtual Conference summary14 Oct, 2025

Pipeline overview and innovation

  • TN-201 and TN-401 are AAV9-based gene therapies targeting MYBPC3-positive HCM and PKP2-positive ARVC, respectively, both using cardiomyocyte-specific promoters with unique IP for TN-201.

  • TN-201 addresses the underlying genetic cause of HCM, especially for non-obstructive patients not eligible for current therapies like Camzyos.

  • TN-401 targets the leading genetic cause of arrhythmogenic cardiomyopathy, addressing a large orphan population with high unmet need.

  • Both programs leverage AAV9's robust safety and efficacy profile, operating at lower doses than peers.

  • Advanced protein quantification methods using mass spectrometry ensure robust measurement of therapeutic impact.

Clinical data highlights and upcoming milestones

  • Interim MyPeak-1 data for TN-201 showed safety, high transduction, increased RNA/protein, and clinical improvements in severe, refractory HCM patients.

  • All three initial TN-201 patients improved to NYHA Class I, indicating no daily living impact from disease.

  • Additional data, including baseline biopsy comparisons and one-year durability, will be presented at AHA as a late-breaking session.

  • TN-401 preclinical data demonstrated prevention of arrhythmia, fibrosis, and cardiac remodeling, with high survival benefit in models.

  • First clinical data from RIDGE-1 for TN-401, focusing on safety and biopsy results, is expected in Q4, with further dose escalation ongoing.

Competitive landscape and strategic positioning

  • TN-201 is positioned as the only therapy directly restoring the missing protein and potentially suitable for pediatric and severe cases.

  • Current standard-of-care and pipeline therapies do not address the genetic root cause in HCM or ARVC.

  • The company is cautious in data release, aiming for robust, interpretable results and meaningful peer comparisons.

  • Accelerated approval pathways may leverage protein as a surrogate biomarker, emphasizing the importance of rigorous quantification.

  • Ongoing engagement with investors and the medical community is prioritized around key data releases.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Tenaya Therapeutics earnings date

Logotype for Tenaya Therapeutics Inc
Chardan’s 9th Annual Genetic Medicines Conference21 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Tenaya Therapeutics earnings date

Logotype for Tenaya Therapeutics Inc
Chardan’s 9th Annual Genetic Medicines Conference21 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Tenaya Therapeutics Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for heart disease. The company's approach involves multiple therapeutic modalities, including gene therapy, cellular regeneration, and precision medicine, to address both rare genetic and prevalent forms of cardiovascular disease. Tenaya's research aims to target the underlying causes of heart disease, offering potential treatments for conditions that currently have limited therapeutic options. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage